Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing

Cell spheroids: the new frontiers in in vitro models for cancer drug validation

(2016) Maria Chatzinikolaidou   DRUG DISCOVERY TODAY

Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma

(2015) Vasilios Liapis et al.   CANCER LETTERS

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

(2015) Mitesh J. Borad et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving drug delivery to solid tumors: Priming the tumor microenvironment

(2015) Iftikhar Ali Khawar et al.   JOURNAL OF CONTROLLED RELEASE

Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing

(2015) Xue Gong et al.   PLoS One

Three-dimensional in vitro tumor models for cancer research and drug evaluation

(2014) Xian Xu et al.   BIOTECHNOLOGY ADVANCES

3D tumor models: history, advances and future perspectives

(2014) Parul Benien et al.   Future Oncology

Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

(2014) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

(2013) A. Italiano et al.   ANNALS OF ONCOLOGY

Advanced chondrosarcomas: role of chemotherapy and survival

(2013) A. Italiano et al.   ANNALS OF ONCOLOGY

3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing

(2013) Paola Longati et al.   BMC CANCER

Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma

(2013) Jolieke G. van Oosterwijk et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance

(2013) David Monderer et al.   LABORATORY INVESTIGATION

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

The role of tumour–stromal interactions in modifying drug response: challenges and opportunities

(2013) Douglas W. McMillin et al.   NATURE REVIEWS DRUG DISCOVERY

Three-dimensional cell culture: the missing link in drug discovery

(2012) Susan Breslin et al.   DRUG DISCOVERY TODAY

Association of Elevated HIF-2α Levels with Low Beclin 1 Expression and Poor Prognosis in Patients with Chondrosarcoma

(2011) Changbao Chen et al.   ANNALS OF SURGICAL ONCOLOGY

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

(2011) G. J. Weiss et al.   CLINICAL CANCER RESEARCH

Therapeutic targeting of tumor–stroma interactions

(2011) Stephen Hiscox et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

(2011) Kristen N. Ganjoo et al.   ONCOLOGY

Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours

(2010) Stephane Boeuf et al.   HISTOPATHOLOGY

Multicellular tumor spheroids: An underestimated tool is catching up again

(2010) Franziska Hirschhaeuser et al.   JOURNAL OF BIOTECHNOLOGY

Anticancer drug development: the grand challenges

(2010) William N. Hait   NATURE REVIEWS DRUG DISCOVERY

Adhesion-mediated apoptosis resistance in cancer

(2009) Mike-Andrew Westhoff et al.   DRUG RESISTANCE UPDATES

Recent advances in three-dimensional multicellular spheroid culture for biomedical research

(2008) Ruei-Zhen Lin et al.   Biotechnology Journal